Frequency of blood transfusions for anemia due to chemotherapy in ovarian cancer patients. Thoughts to the guidelines modified in 2006 for the treatment of anemic cancer patients by the European Organisation for Research and Treatment of Cancer;A petefészekrákos betegek kemoterápiája kapcsán kialakuló anémia kezelésére adott vértranszfúziók gyakorisága. Gondolatok az Európai Rákkutatási és Kezelési Szerveset 2006-ban módosított irányelveihez

Orvosi Hetilap

Volumn 148, Issue 45, 2007, Pages 2133-2137

  Lehoczky, Ottó ^a,b   Pulay, Tamás ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^b Ráth György U 7 9   (Hungary)

Author keywords

Anemia; Chemotherapy; Erythropoetin; Ovarian cancer; Transfusion

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; ERYTHROPOIETIN; ETOPOSIDE; GEMCITABINE; HEMOGLOBIN; PACLITAXEL;

ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL PRACTICE; CLINICAL PROTOCOL; DISEASE SEVERITY; ERYTHROCYTE TRANSFUSION; EUROPE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRACTICE GUIDELINE;

EID: 36348951555     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2007.28188     Document Type: Article

References (31)

1. Harper, P, Littlewood, T: Anaemia of cancer, impact on patient fatigue and long-term outcome. Oncology, 2005, 69, Suppl. 2, 2-7.
2. Bokemeyer, C., Aapro, M. S., Courdi, A. és mtsai: EORTC guidelines for the use of erythropoictic proteins in anaemic patients with cancer. Eur. J. Cancer., 2004, 40, 2201-2216.
3. Bokemeyer, C., Aapro, M. S., Courdi, A. és mtsai: EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer, 2006 update. Eur. J. Cancer., 2007, 43, 258-270.
4. Ludwig, H. az ECAS Tanácsadótestülete is rísztvevoi nevében: European Cancer Anaemia Survey (ECAS). How big is the problem? Az "Újdonságok a rákos vérszegénység kezelésében 3. Oktatási Szimpózium" absztraktjai. Orthobiotech., Wien, 2003, 6.
5. CTC (Common Toxicity Criteria). http,//ctep.cancer.gov/forms/ CTCv20_4-30-992.pdf Let doltés 2007. júdnius 3.
6. Leboczky O. és Pulay T: A vŕszegńysǵ gyakorisiga petefśzekráos betegekben, a saját adatok felmŕésé az Európai Rákos Vŕszegæcnység Vizsgálat (ECAS) eredményei kapcsán. Orv. Hetil, 2003, 144, 2225-2228.
7. Ludwig, H., Van Belle, S., Barrett-Lee, P. és mtsai: The European Cancer Anaemia Survey (ECAS), a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur. J. Cancer, 2004, 40, 2293-2306.
8. Barrett-Lee, P J., Ludwig, H, Birgegard, G. és mtsai: Independent risk factors for anemia in cancer patients receiving chemotherapy, results from the European Cancer Anaemia Survey. Oncology, 2006, 70, 34-48.
9. Tas, E, Eralp, Y, Basaran, M. ás mtsai: Anemia in oncology practice, relation to diseases and their therapies. Am J. Chn. Oncol., 2002, 25, 371-379.
10. Bolis, G., Scarfone, G., Giardina, G. és mtsai: Associazione per la Ricerca in Ginecologia Oncologia (ARGO 96) Study Group. Carboplatin alone vs carboplatin plus epidoxorubicin as second-fine therapy for cisplatin- or carboplatin-sensitive ovarian cancer. Gynecol. Oncol., 2001, 81, 3-9.
11. Muggia, F. M., Braly, P S., Brady, M. F és mtsai: Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer, a gynecologic oncology group study. J. Clin. Oncol., 2000, 18, 106-115.
12. Thigpen, J. T., Blessing, J. A., Olt, G. és mtsai: Cisplatin as second-fine therapy in ovarian carcinoma treated initially with single-agent paclitaxel, a Gynecologic Oncology Group study. Gynecol. Oncol., 2003, 90, 581-586.
13. D'Agostino, G., Amant, F, Berteloot, P és mtsai: Phase It study of gemcitabine in recurrent platinum- and pactitaxel-resistant ovarian cancer. Gynecol. Oncol., 2003, 88, 266-269.
14. Gordon, A. N., Fleagle, J. T, Guthrie, D. és mtsai: Recurrent epithelial ovarian carcinoma, a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol., 2001, 19, 3312-3322.
15. Campos, S. M., Penson, R. T, Mays, A. R. és mtsai: The clinical utility of tiposomal doxorubicin in recurrent ovarian cancer. Gynecol. Oncol., 2001, 81, 206-212. 16 McGuire, W P, Blessing, J. A., Bookman, M. A. is mtsai: Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma. A Gynecologic Oncology Group Study. J. Clin. Oncol., 2000, 18, 1062-1067.
16. Rose, P. G., Blessing, J. A., Mayer, A. R. és mtsa: Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma, a Gynecologic Oncology Group study. J. Clin. Oncol., 1998, 16, 405-410.
17. Alici, S., Saip, P., Eralp, Y és mtsai: Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC). Am. J. Clin. Oncol., 2003, 26, 358-362.
18. Eckhardt S., Hernadi Z., Thurzo L és mtsai: Phase II clinical evaluation of etoposide (VP-16-213, Vepesid) as a secondline treatment in ovarian cancer. Results of the South-East European Oncology Group (SEEOG) Study. Oncology, 1990, 47, 289-295.
19. McGuire, W. P, Hoskins, W J., Brady, M. F. és mrsai: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med., 1996, 334, 1-6.
20. Papadimitriou, C. A., Fountzilas, G., Aravantinos, G. és mtsai: Hellenic Cooperative Oncology Group Study. Second- line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study. Gynecol. Oncol., 2004, 92, 152-159.
21. Ray-Coquard, L, Bachelot, T, Guastalla, J. P. és mtsai: Epirubicin and pactitaxel (EPI-TAX regimen) for advanced ovarian cancer after failure of platinum-containing regimens. Gynecol. Oncol., 2003, 88, 351-357.
22. Pignata, S., Scambia, G., Pisano, é is mtsa: A multicentre phase II study of carboplatin plus pegylated hposomal doxorubicin as first-line chemotherapy for patients with Advanced or recurrent endometrial carcinoma, the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group. Br. J. Cancer, 2007, 96, 1639-1643.
23. Pignata, S., Scambia, G., Savarese, A. és mtsai: MITO Investigators. Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemother- apy in patients with ovarian cancer, preliminary results of the MITO-2 randomized trial. BMC. Cancer, 2006, 6, 202.
24. 25 Chauvergne, J., Chinet-Cbarrot, P., Stockle, E. és mtsai: Association de carboplatine et étoposide dans le traitement des rechutes des cancers épithéhaux de Fovaire. Bulletin du Cancer, 1996, 83, 315-323.
25. 26 Massacesi, C., Bascioni, R., Cellerino, R. is mtsai: Cisplatin, epirubicin and cyclophosphamide (PEC) in the treatment of advanced ovarian cancer. J. Exp. Clin. Cancer Res., 2000, 19, 13-16.
26. Hensley, M. L., Lebeau, D., Leon, L. F és mtsai: Identification of risk factors for equiring transfusion during front-tine chemotherapy for ovarian cancer. Gynecol. Oncol., 2001, 81, 485-489.
27. Heddens, D., Alberts, D. S., Hannigan, E. V és mtsai: Prediction of the need for red cell transfusion in newly diagnosed ovarian cancer patients undergoing platinum-based treatment. Gynecol. Oncol., 2002, 86, 239-243.
28. Bosze P., Mayer Á., Thurzó L. és mtsai: Kemoterápiában rẃszesülo vérszegény daganatos betegek kezelése rekombináns humán erythropoetinnel. Orv. Hetil., 1995, 136, 2567-2572.
29. Dicato, M.: Anemia in Cancer, Some Pathophysiological Aspects. The Oncologist, 2003, 8, S uppl. 1, 19-21.
30. Leyland-jones, B., Semiglazov, V, Pawlicki, M. és mtsai: Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-tine chemotherapy, a survival study. J. Clin. Oncol., 2005, 23, 5960-5972.
31. Vadhan-Raj, S., Skibber, J. M., Crane, C. és mtsai: Randomised, double-blind, placebo-controlled trial of epoetin alfa (Procrit) in patients with rectal and gastric cancer undergoing chemo-radiotherapy followed by surgery: Early termination of the trial due to increased incidence of thromboembolic events. Blood, 2004, 104, A2915.